CDK1 and lung cancer: These results not only establish a metabolic mechanism for NiNP-induced cancer progression but also identify the CDK1-mediated axis as a novel regulatory pathway and API as its corresponding protective agent, suggesting a potential targeted strategy for managing nanomaterial-related lung cancer.